

South Korea approves redness reliever eye drops by Bausch + Lomb

25 January 2021 | News

LUMIFY is the first and only over-the-counter eye drop developed with low dose brimonidine tartrate 0.025% for the relief of redness of the eye due to minor eye irritations



Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc announced that LUMIFY (brimonidine tartrate ophthalmic solution 0.025%) redness reliever eye drops have received approval from the Ministry of Food and Drug Safety (MFDS) in South Korea.

LUMIFY is the first and only over-the-counter eye drop developed with low dose brimonidine tartrate 0.025% for the relief of redness of the eye due to minor eye irritations. Unlike other redness relievers, LUMIFY selectively targets redness, with a reduced risk of certain side effects, including rebound redness and loss of efficacy over time, when used as directed.

"The approval of LUMIFY in South Korea marks another step in our global rollout of these innovative redness reliever eye drops," said Thomas J Appio, President, Bausch + Lomb/International. "LUMIFY will be a welcome addition to our portfolio of eye health products in South Korea, and we expect LUMIFY will be available to consumers in South Korea in the second half

of 2021.”

Additional regulatory submissions for LUMIFY are underway in multiple countries.